Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Condition:   Clear Cell Renal Cell Carcinoma
Intervention:   Biological: XmAb819
Sponsor:   Xencor, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 28, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments